Blog Layout

Okur-Chung neurodevelopmental syndrome: Implications for phenotype and genotype expansion

Apr 11, 2024

Link to Paper: https://doi.org/10.1002/mgg3.2398


Authors: Haitian Nan, Min Chu, Jing Zhang, Deming Jiang, Yihao Wang and Liyong Wu

Research Explained By: Dr. Jennifer Hochscherf


Research Explained Summary:

In this clinical report, the authors describe a novel variant in the CSNK2A1 gene in an OCNDS family. The 31-year-old patient showed abnormal eating habits (a strong predilection for sweets and sugary beverages), recurrent seizures, language impairment and limb weakness. Her neurodevelopment was within the normal range. She experienced her first seizure at the age of 29 and subsequently had recurrent seizure episodes. Further symptoms included involuntary facial twitching, chewing coordination issues, memory decline, visual and auditory hallucinations and daily episodes of limb rigidity and spasms.


Whole Exome Sequencing (WES) was conducted involving the patient, mother, and father. This technique revealed a mutation in the CSNK2A1 gene that was passed on from mother to daughter. The mother exhibited no significant developmental impairments nor intellectual disability but possessed a susceptibility to infections. The mutation in the CSNK2A1 gene that was identified in the patient and her mother is the duplication of the base thymine at position 967 of the coding sequence of the CSNK2A1 gene.


A mutation that adds a new base or deletes a base causes a shift in the reading frame, which is called a frame shift mutation. This leads to completely different building blocks being lined up than actually intended in the construction plan after the mutation site. This often leads to a stop codon, which is the sign to end the linking of building blocks. The cell owns a quality control mechanism that recognizes the mRNAs that harbor such premature stop codons and degrades them to prevent the production of a shortened protein, called nonsense-mediated decay.


The mRNA with the frame shift mutation could not be detected in the study, which indicates that the mRNA is degraded and that the defective CK2alpha protein is not produced. The CSNK2A1 variant is therefore called a “null variant” since no protein product is made. There are always two copies of the CSNK2A1 gene in the cell, one from the father and one from the mother. Hence, there is one copy with the correct sequence in each of the patient's cells, which in this family comes from the father. The study found that the total mRNA transcribed from the CSNK2A1 gene was reduced by around 50% compared to healthy individuals. This suggests that the disease mechanism is due to the presence of less CK2a as compared to individuals without OCNDS.


Many CSNK2A1 variants that have been identified in OCNDS patients carry missense mutations. This means that only one building block of the protein is replaced because of the mutation and the protein continues to be produced although its function is altered. Compared to patients with this type of mutation, the patient presented in the clinical report and her mother have significantly milder symptoms. Other patients with CSNK2A1 null variants show a significantly lower frequency of symptoms, such as speech deficits, dysmorphic facial features, or intellectual disability.


Thus, this study offers insights into the spectrum of clinical manifestations associated with OCNDS and sheds light on the relationship between the mutation at the DNA level and the clinical presentation. Specifically, it highlights that individuals with null variants in the CSNK2A1 present with a milder clinical presentation than individuals with missense variants.


Additional Scientific Background for this paper:

The CSNK2A1 gene is the blueprint for the CK2alpha protein and determines the sequence in which various building blocks, so-called amino acids, are linked to form a long chain. This blueprint is written down in the DNA with four different bases (cytosine [C], guanine [G], adenine [A] and thymine [T]) like letters in a book. Three consecutive bases, known as a codon, contain the information which building block is to be incorporated. To learn more about codons, visit this link.


Between the blueprint on the DNA and the actual assembly of the protein from the individual building blocks, there is another important step: The blueprint is transcribed into a messenger RNA (mRNA). Certain modifications ensure that it ultimately only contains the information for building the protein -like extracting the essential chapters of the construction manual.

Learn More

FAQS RESOURCES REGISTER DONATE
Newborn Genetic Screenings
By Penelope Gatlin 05 Oct, 2023
By Penelope Gatlin October 2023 When our son was born in 2012, he was hypotonic, severely jaundiced, had feeding difficulties and features such as epicanthic folds and small low set ears. We were told immediately that doctors had suspicions of a genetic syndrome. At that time, genetic testing was limited and once abnormal karyotype, Trisomy 21, and Fragile X were ruled out, we left the hospital with an 8 day old and no diagnosis. While no testing was available at that time to identify the ultra-rare syndrome my child had, because it wouldn’t even be identified until 4 years later, I can only imagine the difference it would have made to our journey to have such an answer sooner. Instead, we were unprepared and actually unaware that just because a diagnosis hadn’t been made then that it didn’t mean there wasn’t in fact a rare disease present. Instead, we dealt with issues as they came and worried and wondered what would be next. From feeding issues and reflux and constipation, to low muscle tone and delayed walking, to speech delay, social and emotional delays, toileting delays, diagnoses of developmental delay, anxiety, situational mutism, sensory processing disorder, and autism, until finally genetic testing that revealed the diagnosis that we’d waited 7 years to find out. While receiving a diagnosis can seem scary, not having an answer but knowing there must be one is even more so. In 2019, the day I clicked onto the portal to see the test results, the largest word on the page was POSITIVE. My heart stopped for a second. For the first time, I read the words “Okur-Chung Neurodevelopmental Disorder.” A roller coaster of emotions ensued, including sadness that we hadn’t known this from birth because it would have made us as parents more prepared, and given us more understanding about what might arise next. Relief that we had an answer, grateful that this syndrome had been identified and that he was among one of the first hundred diagnosed with it in the world, and glad we had the privilege to have access to the testing. Excitement that we can participate in future research. Fright that there’s so much we don’t know about OCNDS, and happiness that there is something that we do. A feeling that we are no longer shooting in the dark and have a small but supportive community to rely on and learn from. I am hopeful that one day, all newborns with features like my child will be tested at birth, so parents can have access to the answers, support, and interventions and therapies that can best help their child as soon as possible.
Autism Diagnosis
By Terri Jordan 23 Aug, 2023
For 16 years, my child displayed numerous symptoms that left us searching for answers, but a genetic diagnosis remained elusive. I considered having my child evaluated for autism to shed light on their situation. However, when I reached out to teachers, doctors, and therapists, I received frustrating responses: “Your child is too friendly to be autistic.” This statement made me doubt the possibility of autism because my child was sociable. “Your child can transition from one activity to another – they are not autistic.” Hearing this, I questioned whether my child’s ability to shift activities invalidated the need for an autism evaluation. “Your child can look me in the eye and answer questions – they are not autistic.” Observations like this made me second-guess the idea of autism, even though my child faced various challenges. “Getting a diagnosis that does not apply to your child would be a big waste of money.” Despite my persistent concerns, this cautionary advice about the evaluation costs left me hesitant. We finally pursued an evaluation when my son turned 20, and it confirmed that he is indeed on the autism spectrum (severe side). Looking back, I regret not taking this step sooner. I should have pursued the autism diagnosis before we received the genetic diagnosis. There are several benefits we could have gained as a family if we had pursued an early diagnosis: “Early Support Is Crucial:” I now realize that early intervention could profoundly impact my child’s development. We could have accessed the right services and therapies much earlier with a diagnosis. “Understanding My Child Better:” I struggled to comprehend my child’s behaviors and communication difficulties. An earlier diagnosis could have provided insights into their unique needs and thought processes. The education could also help me explain how to react to my child’s behavior to family members. “Tailored Guidance and Resources:” A diagnosis could have opened doors to specialized resources and guidance, enabling me to provide the best possible support for my child. “Connecting with Others:” Being part of the autism community might have connected us with other parents who understand our experiences. Sharing and learning from each other could have been invaluable. “Planning for the Future:” Knowing more about my child’s strengths and challenges could have helped me better plan their future, including education, career, and overall well-being. Depending on your location, many states offer funding and support if your child has an autism diagnosis. I wish I listened to my voice instead of being swayed by experts who didn’t fully understand my child’s situation. Ultimately, I know this decision is significant, requiring careful consideration by parents. Looking back, I wish I had trusted my instincts and sought an evaluation sooner to improve my child’s life.
Share by: